Loading stock…

BioMarin Pharmaceutical Inc. (BMRN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

BioMarin Pharmaceutical Inc.

BMRNMarket cap $11BPrice $54.9

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

BioMarin develops treatments for rare genetic diseases that most drugmakers ignore because the patient pools are too small to matter. It pioneered the entire market for ultra-rare disorders, turning tiny patient populations into a multi-billion dollar business model.

In Bastion Portfolios?

52W Return+3%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+15%8

Revenue Forecast

Rev CAGR (1y)+21%8

Rev CAGR (3y)+15%8

Rev CAGR (5y)+12%8

Earnings Forecast

EPS Growth Y+1+183%10

EPS Growth Y+2+32%9

EPS Growth Y+3+20%8

Quality

Margins

EBIT Margin15%6

Net Income Margin2%3

Free Cash Flow Margin22%8

Debt

Net Debt/EBITDA5.12

Efficiency

ROE1%2

ROA1%2

Earnings Stability55

GEAR+STRONG70

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)99

P/E Ratio (Forward 3y)710

P/BV1.77

EV Multiples

EV/EBITDA Fwd144

EV/EBIT Fwd175

Yield

Free Cash Flow Yield6.9%8

Dividend Yieldna–

Momentum

Short term

1 month return-15%1

3 month return-8%4

YTD return-8%4

Mid term

Price vs 52wHigh77%5

1 year return+2%5

Long term

3 year return-37%1

5 year return-29%2

Risk Shield

Price Risk

Beta0.57

Volatility34%6

Free Cash Flow

Free Cash Flow Margin22%8

Free Cash Flow Yield6.9%8

Quality

ROCE6%4

Earnings Stability55

Net Debt/EBITDA5.12

02Growth

Is it actually growing, and how fast?

BMRNBioMarin Pharmaceutical

Revenue FY25$3.2B

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y+21%8

Revenue, next 3Y, CAGR+15%8

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+183%10

EPS growth, FY27E+32%9

EPS growth, FY28E+20%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 15%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 15%/yr over the last 3 years and is set to keep growing around 15%/yr.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 32%/yr vs revenue 15%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-15%1

3-month return-8%4

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return+2%5

3-year return-37%1

5-year return-29%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's up 2% over the past year, but 23% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (-8%) and so far this year (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-37% over three years and -29% over five), behind 80% of the market.

The stock is underperforming over the past month (-15%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on BioMarin Pharmaceutical Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

BMRNBioMarin Pharmaceutical

Revenue FY25$3.2B

GROWTH RATING↗

STRONG83 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y+21%8

Revenue, next 3Y, CAGR+15%8

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+183%10

EPS growth, FY27E+32%9

EPS growth, FY28E+20%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 83% of companies worldwide.

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 15%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 15%/yr over the last 3 years and is set to keep growing around 15%/yr.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 32%/yr vs revenue 15%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK14 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-15%1

3-month return-8%4

YTD return-8%4

MID & LONG-TERM▾SCORE

% of 52-week high77%5

1-year return+2%5

3-year return-37%1

5-year return-29%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's up 2% over the past year, but 23% below its 52-week high. That is right in line with the market.

Returns sit at the market level over three months (-8%) and so far this year (-8%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-37% over three years and -29% over five), behind 80% of the market.

The stock is underperforming over the past month (-15%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on BioMarin Pharmaceutical Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community